Med. praxi. 2012;9(4):151-155

Treatment of atrial fibrillation from the point of view of a general practitioner

doc.MUDr.Miloš Táborský, CSc., FESC, MBA, doc.MUDr.Petr Heinc, Ph.D.
I. interní klinika &ndash, kardiologická LF UP a FN Olomouc

Currently, at least 200,000 patients with atrial fibrillation can be identified in the Czech population. Along with obesity, hypertension, heart

failure, and diabetes, it is among the cardiovascular epidemics of the third millennium. Diagnosis and treatment of these patients begins and

ends in the surgeries of general practitioners. Knowledge of the recent guidelines for treatment of atrial fibrillation from the point of view of

a general practitioner is essential for the further fate of these patients, particularly for the prevention of thromboembolic complications.

Keywords: atrial fibrillation, anticoagulant therapy, antiarrhythmic agents, catheter ablation

Published: April 25, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Táborský M, Heinc P. Treatment of atrial fibrillation from the point of view of a general practitioner. Med. praxi. 2012;9(4):151-155.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001; 86: 516-521. Go to original source... Go to PubMed...
    2. Čihák R, Heinc P, Haman L, et al. Fibrilace síní. Doporučený diagnostický a léčebný postup ČKS. http://www.kardiocz.cz/resources/upload/data/355_27-52.pdf.
    3. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26: 2422-2434. Go to original source... Go to PubMed...
    4. Nabauer M, Gerth A, Limbourg T, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009; 11: 423-434. Go to original source... Go to PubMed...
    5. Jabaudon D, Sztajzel J, Sievert K, et al. Usefulness of ambulatory 7-day ECG monitoring for the detection of atrial fibrillation and flutter after acute stroke and transient ischemic attack. Stroke 2004; 35: 1647-1651. Go to original source... Go to PubMed...
    6. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867. Go to original source... Go to PubMed...
    7. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010; 137: 263-272. Go to original source... Go to PubMed...
    8. Pisters R, Lane DA, Nieuwlaat R, et al. A novel userfriendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. CHEST 2010; 138(5): 1093-1100. Go to original source... Go to PubMed...
    9. Václavík J, Táborský M, Antiplatelet therapy in the perioperative period, Eur J Intern Med 2011; 22: 26-31. Go to original source... Go to PubMed...
    10. Lip GY, Huber K, Andreotti F, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost 2010; 103: 13-28. Go to original source... Go to PubMed...
    11. Connoly Sj, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patiens with atrial fibrillation, N Engl J Med 2009; 361: 1139-1151. Go to original source... Go to PubMed...
    12. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2010; 365: 883-891. Go to original source... Go to PubMed...
    13. Granger CB, Alexander JH, McMuray JJV, et al. Apixaban versus warfarin in patiens with atrial fibrillation. E Engl J Med 2011; 365: 981-992. Go to original source... Go to PubMed...
    14. AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833. Go to original source... Go to PubMed...
    15. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-1840. Go to original source... Go to PubMed...
    16. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358: 2667-2677. Go to original source... Go to PubMed...
    17. Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 2010; 362: 1363-1373. Go to original source... Go to PubMed...
    18. Calkins H, Reynolds MR, Spector P, et al. I. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol 2009; 2: 349-361. Go to original source... Go to PubMed...
    19. Guidelines for the management of atrial fibrillation: The Task Force for the Management of trial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 2010; 31(19): 369-2429.
    20. Táborský M, et al. Fibrilace síní, ISBN 978-204-2572-0, nakladatelství Mladá fronta, divize Medical Services, edice Postgraduální medicíny, 2011.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.